These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

924 related items for PubMed ID: 20484441

  • 21. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 22. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
    Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, Uslu I, Kanmaz B.
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
    [Abstract] [Full Text] [Related]

  • 23. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 24. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
    Niedermoser S, Chin J, Wängler C, Kostikov A, Bernard-Gauthier V, Vogler N, Soucy JP, McEwan AJ, Schirrmacher R, Wängler B.
    J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
    [Abstract] [Full Text] [Related]

  • 25. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 26. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

  • 27. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors.
    Gålne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenström E, Sundlöv A, Trägårdh E.
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [Abstract] [Full Text] [Related]

  • 28. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
    Łapińska G, Bryszewska M, Fijołek-Warszewska A, Kozłowicz-Gudzińska I, Ochman P, Sackiewicz-Słaby A.
    Nucl Med Rev Cent East Eur; 2011 Dec; 14(1):16-20. PubMed ID: 21751167
    [Abstract] [Full Text] [Related]

  • 29. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J, Lewington V, Krolicki L.
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [Abstract] [Full Text] [Related]

  • 30. 18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.
    Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, den Broeck BV, Laenen A, Clement PM, Geboes K, Cutsem EV, Stroobants S, Verslype C, Bormans G, Deroose CM.
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [Abstract] [Full Text] [Related]

  • 31. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.
    J Clin Oncol; 2016 Feb 20; 34(6):588-96. PubMed ID: 26712231
    [Abstract] [Full Text] [Related]

  • 32. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.
    J Nucl Med; 2001 Feb 20; 42(2):213-21. PubMed ID: 11216519
    [Abstract] [Full Text] [Related]

  • 33. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors.
    Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, Lundqvist H, Sundin A, Lubberink M.
    J Nucl Med; 2013 Oct 20; 54(10):1755-9. PubMed ID: 23929824
    [Abstract] [Full Text] [Related]

  • 34. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation.
    Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, Stokkel MPM.
    Eur J Nucl Med Mol Imaging; 2019 Mar 20; 46(3):696-703. PubMed ID: 30097670
    [Abstract] [Full Text] [Related]

  • 35. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.
    Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS.
    J Nucl Med; 2015 Jan 20; 56(1):70-5. PubMed ID: 25500825
    [Abstract] [Full Text] [Related]

  • 36. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE.
    Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M.
    J Nucl Med; 2020 Feb 20; 61(2):217-221. PubMed ID: 31302632
    [Abstract] [Full Text] [Related]

  • 37. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.
    Cancer; 2008 Jun 20; 112(11):2447-55. PubMed ID: 18383518
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J.
    J Nucl Med; 2017 Jan 20; 58(1):91-96. PubMed ID: 27516446
    [Abstract] [Full Text] [Related]

  • 39. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B.
    Nucl Med Commun; 2013 Aug 20; 34(8):727-32. PubMed ID: 23728519
    [Abstract] [Full Text] [Related]

  • 40. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.
    Malmberg C, Ripa RS, Johnbeck CB, Knigge U, Langer SW, Mortensen J, Oturai P, Loft A, Hag AM, Kjær A.
    J Nucl Med; 2015 Dec 20; 56(12):1895-900. PubMed ID: 26429961
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.